DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20182041

A study on rapid diagnosis (by PCR) and cost-effective treatment of pulmonary mycosis

Saurabh Kumar, Iram Shaifali, Shalini Chandra

Abstract


Background: Incidence of Pulmonary Mycosis is rampantly growing in critically ill patients. This study was designed to comparatively evaluate conventional and molecular method-Polymerase Chain Reaction (PCR) for detecting Candida and Aspergillus species in Brocho-Alveolar Lavage (BAL) samples and secondarily to find out the Cost-Effective treatment for Pulmonary Mycosis.

Methods: In this study 100 BAL-specimens were collected from patients suspected of Pulmonary Mycosis. These samples were examined for Aspergillus and Candida species by preparation of wet smear using potassium hydroxide, Gram staining, Culture media and Polymerase Chain Reaction (PCR). For Cost-Effectiveness analysis(CEA), a decision tree model was constructed for Anidulafungin and Fluconazole The probability of treatment success and mortality rate were extracted from published Randomized Control Trials. Incremental Cost Effectiveness Ratio (ICER) was calculated.

Results: Out of 100 samples, 22 were found to be positive for mycotic infections, 9 were detected as Candida and 13 as Aspergillus. On comparing with KOH and Culture, it was observed that all KOH positive and all Culture positive fungal infections were PCR positive. In no cases PCR negative was identified either culture or KOH positive. This establishes the superiority of PCR over conventional diagnostic methods. Anidulafungin was associated with an Incremental Cost Effectiveness Ratio (ICER) of INR 1,13,217 per LY saved, which was below the implicit ICER threshold for India.

Conclusions: PCR is a novel molecular method for early and definitive diagnosis of fungal infection and Aidulafungin appears to be the cost-effective drug for treatment of Pulmonary Mycosis.


Keywords


Anidulafungin, Cost-effectiveness, Fluconazole, ICER, PCR, Pulmonary mycosis

Full Text:

PDF

References


Meersman W, Lagrauk, Maertens J, Van Wijngarden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45(2):205-16.

Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30(4):782-800.

Randhawa HS. Respiratory and Systemic mycosis: an overview. Indian J Chest Dis Allied Sci. 2000;42:207-19.

AM Tortorano, J Peman, H Bernhardt. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23:317-22.

Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intens Care. 2011;1:37.

Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.

Tascini C, Sbrana F, Cardinali G. Arterial blood culture to hasten the diagnosis of candidemia in critically ill patients. Intensive Care Med. 2014;40:1059-60.

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008 Jun 15;46(12):1813-21.

Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. Journal of clinical microbiology. 2011 Feb 1;49(2):665-70.

PG Pappas, CA Kauffman, D Andes. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.

Cornely OA, Bassetti M, Calandra T. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19-37.

Scudeller L, Viscoli C, Menichetti F. An Italian consensus for invasive candidiasis management (ITALIC). Infection 2014;42:263-79.

Liu W, Dong D, Yang Z, Zou D, Chen Z, Yuan J, et al. Polymerase Spiral Reaction (PSR): A novel isothermal nucleic acid amplification method. Scientific reports. 2015 Jul 29;5:12723.

Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res. 2011;16:180-6.

Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. New England Journal of Medicine. 2007 Jun 14;356(24):2472-82.

Pasqualotto AC, Nedel WL, Machado TS, Severo LC. Risk factors and outcome for nosocomial breakthrough candidaemia. Infect. 2005;52:216-22.

Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin. Microbiol. Rev. 2011;24:247-80.

Moran C, Grussemeyer CA, Spalding JR, Benjamin DK, Jr, Reed SD. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control. 2010;38:78-80.

Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 2005;49:3640-5.

Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004 Apr 1;42(4):1519-27.

Kousha M. Pulmonary Aspergillosis: A Clinical Review Eur Respi Rev. 2014;20:121,156-74.

Mathavi S, Shanker R, Kavitha G, Priyadarshini I. A study on prevalence of pulmonary candidiasis among tuberculosis patients and use of chromagar in identification of Candida species. J Drug Del Ther. 2014;4:3.

Al-Khalidi AA, Faraj MJ, Faraj MK. Isolation and identification of fungi associated with chronic respiratory infections in human and bovine. Al-Anbar J Vet Sci. 2012;5:85-93.

Hardak E, Yigla M, Avivi I, Fruchter O, Sprecher H, Oren I. Impact of PCR-based diagnosis of invasive pulmonary aspergillosis on clinical outcome. Bone marrow transplantation. 2009 Nov;44(9):595.

World Health Organization. World health report 2002: reducing risks, promot-ing healthy life. Geneva: World Health Organization; 2002.

Sakharkar P. Draft National Health Policy of India and Determining Cost-effectiveness Threshold. J Basic Clin Pharma. 2017;8:1-3.

Grau S, Garcia-Vargas M, Marti B, Mir N. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain. Poster presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases, 16–19 May, Helsinki, Finland, 2009.

Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Chin Fen Neoh et al: J Antimicrob Chemother. 2011;66:1906-15.

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis: Auzinger et al. BMC Infectious Diseases. 2015;15:463.

Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species. Ou et al. BMC Infectious Diseases. 2017;17:481.